Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting
Retrieved on:
Thursday, October 21, 2021
Oncology, Health, Other Science, General Health, Research, Science, Breast cancer, Cancer, Bladder cancer, Neoplasm, Immunotherapy, ADCC, Patient, Lymphoma, Walter, Society, Breast, Conference, GC, Northwest Biotherapeutics, Society for Immunotherapy of Cancer, NK, Rituximab, Lymphoid leukemia, HER2, SITC, Washington Convention Center, Pharmaceutical industry, HER2+ Solid Tumors, AB-201, Artiva Biotherapeutics, HER2+ SOLID TUMORS, AB-201, ARTIVA BIOTHERAPEUTICS
The full abstract is scheduled to be available on the SITC website on November 9, 2021.
Key Points:
- The full abstract is scheduled to be available on the SITC website on November 9, 2021.
- HER2 is a receptor tyrosine kinase that is overexpressed on many solid tumors, including breast, gastric, and bladder cancers.
- AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy candidate manufactured from cord blood, containing a proprietary HER2 antigen recognition domain.
- Artiva is developing AB-201 for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers.